Amgen, Inc. paying up to $1.25bn for Kyowa Kirin Co., Ltd.’s OX40-targeting KHK4083 in atopic dermatitis marks a significant vote of confidence in a new mechanism of action for a disease in a highly competitive market. There is still unmet need, however, but with a wide variety of therapeutic options approved or in late-stage development, the OX40 inhibitor will need to prove itself when the full Phase II data become available in the second half of 2021.
Thousand Oaks, CA-based Amgen and Tokyo-based Kyowa Kirin announced the deal on 1 June to develop and commercialize KHK4083 in...
